Skip to content


You currently have no items in your basket.

Total (excl. vat) £0.000
View basket & checkout

Tumour Microenvironment

Develop your understanding of the Tumour Microenvironment with Arigo Biolaboratories.

The tumour microenvironment (TME) is the environment around a tumour mass, which consists of many non-cancer cells such as stromal cells, neovessels, immune cells, and extracellular matrix (ECM). The TME plays key roles in tumour initiation, progression, metastasis, recurrence, and drug resistance. Understanding TME is critical for the development of anti-cancer therapies.

Cancer-associated fibroblasts (CAFs)

CAFs are the predominant stromal cells in TME and are associated with all stages of cancer. Targeting CAFs becomes a promising therapeutic strategy for cancer therapy, due to their roles in enhancing cell growth stages that cause the cancer to divide and spread rapidly, as well as inhibiting the immune system by recruiting immunosuppressive cells. Suppressing cytotoxic T lymphocytes (CTLs) in the immune system also leads to tumour escape.

Arigo Biolaboratories CAF-related products:


Angiogenesis of tumour growth occurs in the TME due to uncontrolled cell proliferation, which causes hypoxia. Pro-angiogenic factors stimulate tumour formation, but can also suppress CTL activity.
A combination of anti-angiogenesis therapy and immunotherapy have become important strategies in cancer treatment, as studies have indicated a strong interaction between the two.

Arigo Biolaboratories angiogenesis products:

Tumour immune microenvironment

The tumour immune microenvironment (TIME) contains many important immune cells, such as CTLs and natural killer cells. This component plays a huge role in tumour immune surveillance and tumour immune escape, so researching the TIME is crutial for the development of effective cancer immunotherapy.

Arigo Biolaboratories TIME-related products: